The firm acts on some of Japan’s most prominent transactions, including Bain Capital's $3.3 billion pharma acquisition of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback